- Investopedia•1 hour ago
Big pharma companies eagerly await key decisions on drugs from the FDA next week.
Google faces some tough decisions as the boycott of its YouTube network by advertisers continues to grow.
Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent.
GSK : Summary for GlaxoSmithKline PLC - Yahoo Finance
GlaxoSmithKline plc (GSK)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||41.35 x 200|
|Ask||43.00 x 100|
|Day's Range||42.20 - 42.37|
|52 Week Range||37.20 - 45.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||93.26|
|Dividend & Yield||2.00 (4.74%)|
|1y Target Est||N/A|